Local tolerability and effectiveness of Ketospray® 10% cutaneous spray solution.

医学 耐受性 安慰剂 销售授权 不利影响 药品 临床试验 观察研究 随机对照试验 重症监护医学 药理学 内科学 替代医学 生物信息学 病理 生物
作者
Ion Fulga,Olivera Lupescu,Tiberiu Spircu
出处
期刊:PubMed 卷期号:54 (1 Suppl 4): 23-33
链接
标识
摘要

Orally administrated nonsteroidal anti-inflammatory drugs are effective in the treatment of a variety of acute and chronic pain conditions but their use may be associated with serious systemic adverse effects which are correlated with the therapeutic plasma levels of the drug. In order to minimize the incidence of drug related systemic events, topical formulations of the nonsteroidal anti-inflammatory drugs have been developed. A recently performed review of the evidence from randomized, double-blind, placebo controlled trials with topically applied NSAIDs in the treatment of acute pain confirmed the previously described pain relief effectiveness. For all topical nonsteroidal anti-inflammatory drugs combined, in comparison to placebo, the number needed to treat (NNT) to achieve a clinically meaningful pain relief of 50 % was 4.5 (3.9 to 5.3) for treatment periods of 6 to 14 days. Local skin reactions were generally mild and transient, and did not differ from placebo.The present is an observational, multicenter, open-label, non-interventional, post-authorization safety study as it is defined by Article 21 of the European Clinical Trials Directive 2001/20/EC. The main objective of this study was to evaluate the local tolerability and the therapeutic efficacy of static and pain on movement intensity reduction of Ketospray® 10% cutaneous spray solution administered in accordance with the terms of the marketing authorization and last version of summary of product characteristics approved by National Medicines Agency of Romania.In compliance with the Post-marketing study type, the assignment of the patient to a particular therapeutic strategy fell within current practice. The prescription of the medicine was not subject to compliance with predefined patients' characteristics. No specific, out of the daily practice routine diagnostic, monitoring, instrumental or laboratory assessments were foreseen by the study protocol. Patients' data were collected into respective case report forms. Study medication, Ketoprofen 10% Cutaneous Spray Solution was administered to the affected area at the dose of 3-6 spray puffs, 2-3 times a day, for 7 days. According to the study type, descriptive statistical methods were applied. Since almost half of the patients were treated with combination of the pain relieving medications, sizing of the pain relieving effects, as NNT, between the two groups was made.There were 2020 study subjects in safety and ITT analysis population and 1802 (89%) in PP efficacy analysis population. There were 4 types of injuries: non-complicated strain-sprain (555), soft tissue contusion (323), low back pain (461) and osteoarthritis (681 patients). Ten patients reported 13 side effects of which 10 were recognized by investigators as adverse drug reactions. All side effects were non-serious, listed, application site skin changes. Remarkable reductions of static and pain on movement intensity were experienced by patients irrespective of the type of the injury and the type of the treatment. However, a clinically meaningful benefit of the concomitantly prescribed pain relieving medications was not observed for any type of pain. The lowest NNT (14) was obtained for the reduction of pain at rest in patients with strain-sprain or soft tissue contusions. The highest NNT (283) was for pain at rest in patients treated for the exacerbation of the chronic pain.The results of the current post-authorization study confirm beneficial pain intensity reducing efficacy of Ketospray 10% associated with good local tolerability of 7 days treatment course. Concomitant administration of systemic pain relieving medication did not substantially contribute neither to the relief of pain at rest nor of pain on movement among the subjects of respective study populations.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
赘婿应助小乖采纳,获得10
1秒前
传奇3应助少少采纳,获得10
2秒前
SageHe发布了新的文献求助10
2秒前
3秒前
3秒前
4秒前
充电宝应助小乖采纳,获得10
4秒前
口口完成签到 ,获得积分10
6秒前
pirateharbor发布了新的文献求助10
8秒前
CR7应助懒洋洋采纳,获得20
8秒前
8秒前
drzz发布了新的文献求助10
9秒前
武雨寒发布了新的文献求助10
9秒前
王十三完成签到 ,获得积分10
12秒前
AI_S给AI_S的求助进行了留言
12秒前
彭于晏应助Wellnemo采纳,获得10
13秒前
13秒前
隐形曼青应助科研通管家采纳,获得10
14秒前
科研通AI5应助科研通管家采纳,获得10
14秒前
JamesPei应助科研通管家采纳,获得10
14秒前
14秒前
14秒前
14秒前
科研通AI5应助科研通管家采纳,获得10
14秒前
14秒前
内向月饼完成签到,获得积分10
14秒前
鱼儿发布了新的文献求助10
16秒前
科研通AI2S应助cheems采纳,获得10
17秒前
111完成签到,获得积分10
17秒前
17秒前
18秒前
18秒前
宋宋驳回了张雷应助
18秒前
量子星尘发布了新的文献求助10
18秒前
19秒前
勤奋凝安发布了新的文献求助30
21秒前
游戏人间完成签到 ,获得积分10
21秒前
意林发布了新的文献求助30
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975836
求助须知:如何正确求助?哪些是违规求助? 3520174
关于积分的说明 11201364
捐赠科研通 3256576
什么是DOI,文献DOI怎么找? 1798362
邀请新用户注册赠送积分活动 877539
科研通“疑难数据库(出版商)”最低求助积分说明 806426